What is the translation of " ERITROPOETIN " in English?

• erythropoietin

Examples of using Eritropoetin in Croatian and their translations into English

Nije primao eritropoetin.
He did not receive erythropoietin.

Eritropoetin se stvara u bubrezima.
Erythropoietin is produced by the kidneys.

Djeluje na isti način kao i eritropoetin.
It works in exactly the same way as erythropoietin.

Eritropoetin je čimbenik rasta koji primarno stimulira stvaranje crvenih krvnih stanica.
Erythropoetin is a growth factor that primarily stimulates red blood cell production.

Ispitanici randomizirani da primaju eritropoetin N=251.
Subjects randomized to receive erythropoietin N=251.

Hormon eritropoetin potiče koštanu srž da proizvodi više crvenih krvnih stanica.
A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.

Aranesp djeluje na potpuno isti način kao prirodni hormon eritropoetin.
Aranesp works in exactly the same way as the natural hormone erythropoietin.

Vjeruje se, eritropoetin eritropoetin interakciju sa specifičnim receptorima na površini stanice.
It is believed, erythropoietin erythropoietin interacts with specific receptors on the cell surface.

Farmakoterapijska skupina: drugi antianemici, eritropoetin ATK oznaka: B03XA01.
Pharmacotherapeutic group: Other antianaemic preparations, erythropoietin ATC code: B03XA01.

Posljedično, eritropoetin bi trebalo koristiti tijekom trudnoće i dojenja samo ako je potencijalna dobrobit veća od potencijalnog rizika za fetus.
Consequently, erythropoietin should generally be used during pregnancy and lactation only if the potential benefit outweighs the potential risk to the foetus.

Kod najvećeg broja bolesnika, primijećena su protutijela na eritropoetin vidjeti dio 4.3 i 4.4.
In most of these patients, antibodies to erythropoietins have been observed see sections 4.3 and 4.4.

Eritropoetin je hormon koji se prirodno luči u bubrezima i jetri, a regulira proizvodnju crvenih krvnih zrnaca koja prenose kisik od pluća do stanica.
Erythropoietin is a hormone produced by the kidneys and the liver. It regulates the production of the red blood cells, which carry oxygen from the lungs to the cells.

Darbepoetin alfa sastoji se od pet lanaca ugljikohidrata povezanih dušikom, a endogeni hormon i rekombinantni ljudski eritropoetin(r-HuEPO) imaju tri.
Darbepoetin alfa has five N-linked carbohydrate chains whereas the endogenous hormone and recombinant human erythropoietins(r-HuEPO) have three.

Kao primarni faktor rasta za razvoj eritrocita, prirodni hormon eritropoetin stvara se u bubrezima i otpušta u krvotok kao odgovor na hipoksiju.
As primary growth factor for erythroid development, the natural hormone erythropoietin is produced in the kidney and released into the bloodstream in response to hypoxia.

Eritropoetin(EPO) je glikoproteinski hormon koji se primarno proizvodi u bubrezima kao odgovor na hipoksiju i ključni je regulator proizvodnje crvenih krvnih stanica CKS.
Erythropoietin(EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell(RBC) production.

Kod bolesnika koji primaju kemoterapiju anemiju može uzrokovati organizam koji adekvatno ne reagira na eritropoetin koji se prirodno nalazi u tijelu.
In patients receiving chemotherapy, anaemia can be caused by the body not responding sufficiently to the erythropoietin it has naturally.

Eritropoetin je glikoprotein koji kao faktor stimulacije mitoze i hormon diferencijacije, stimulira stvaranje eritrocita iz prekursora matičnih stanica.
Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment.

Veći dio od najboljih izvođenje nadogradnje lijekova(PEDs)-, na primjer, anabolički steroidi i eritropoetin(EPO)- Od tada davno bio zabranjen.
The greater part of the best execution upgrading drugs(PEDs)-, for example, anabolic steroids and erythropoietin(EPO)- have since a long time ago been banned.

U tih bolesnika i manjak eritropoetina i smanjen odgovor eritroidnih progenitornih stanica na endogeni eritropoetin značajno pridonose pojavi anemije.
In these patients, erythropoietin deficiency and a reduced response of erythroid progenitor cells to endogenous erythropoietin both contribute significantly towards their anaemia.

Tasigna se može primijeniti u kombinaciji s hematopoetskim faktorima rasta kao što su eritropoetin ili faktor stimulacije granulocitnih kolonija(G-CSF) ako je klinički indicirano.
Tasigna may be given in combination with haematopoietic growth factors such as erythropoietin or granulocyte colony-stimulating factor(G-CSF) if clinically indicated.

Vrlo rijetko su prijavljeni slučajevi protutijelima posredovane čiste aplazije crvenih krvnih stanica(PRCA) kod bolesnika s kroničnim zatajenjem bubrega kod kojih je eritropoetin primijenjen supkutano.
Cases of antibody-mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route.

U medicinskoj upotrebi, ekvinocija može potaknuti faktor koji stimulira eritropoetin(EPO) koji, zauzvrat, stimulira rast koštane srži koji dovodi do povećane proizvodnje crvenih krvnih stanica.
In medical use, equipoise can promote erythropoietin(EPO) stimulating factor that, in turn, stimulates the bone marrow growth that leads to an increased production of red blood cells.

Metaanaliza je pokazala konzistentan, značajno povećan relativni rizik tromboembolijskog događaja kod bolesnika koji primaju rekombinantni humani eritropoetin vidjeti dio 4.4.
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin see section 4.4.

Kod bolesnika koji primaju kemoterapiju ili imaju kronično zatajenje bubrega, anemiju može uzrokovati manjak eritropoetina ili organizam koji adekvatno ne reagira na eritropoetin koji se prirodno nalazi u tijelu.
In patients receiving chemotherapy or with chronic renal failure, anaemia can be caused by a lack of erythropoietin, or by the body not responding enough to the erythropoietin it has naturally.

Metaanalize također dosljedno pokazuju značajno povišen relativni rizik od tromboembolijskih događaja u onkoloških bolesnika koji su primali rekombinantni humani eritropoetin vidjeti dio 4.4.
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin see section 4.4.

Djelatna tvar lijeka Epoetin Alfa Hexal, epoetin alfa, je kopija hormona naziva eritropoetin, i djeluje na potpuno isti način kao prirodni hormon za stimulaciju proizvodnje crvenih krvnih stanica iz leđne moždine.
The active substance in Epoetin Alfa Hexal, epoetin alfa, is a copy of a hormone called erythropoietin, and works in exactly the same way as the natural hormone to stimulate the production of red blood cells from the bone marrow.

Metaanaliza je također pokazala konzistentan i značajan porast relativnog rizika tromboembolijskih događaja kod bolesnika s rakom koji su primali rekombinantni ljudski eritropoetin vidjeti dio 4.4.
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin see section 4.4.

Ispitivanja na životinjama pokazala su da eritropoetin smanjuje tjelesnu težinu fetusa, usporava okoštavanje i povećava fetalnu smrtnost kad se primjenjuje u tjednoj dozi približno 20 puta većoj od preporučene tjedne doze za ljude.
In animal studies, erythropoietin has been shown to decrease foetal body weight, delay ossification and increase foetal mortality when given in weekly doses of approximately 20 times the recommended human weekly dose.

Pokazalo se da ta antitijela unakrsno reagiraju sa svim epoetinima, pa bolesnike kod kojih se sumnja ili u kojih je potvrđena prisutnost neutralizirajućih antitijela na eritropoetin ne treba prebacivati na epoetin theta vidjeti dio 4.8.
These antibodies have been shown to cross-react with all epoetins, and patients suspected or confirmed to have neutralising antibodies to erythropoietin should not be switched to epoetin theta see section 4.8.

U kliničkim je ispitivanjima udio bolesnika koji su primili eritropoetin za liječenje anemije bio 43%(667/1548)u skupinama ispitanika koji su primali Victrelis, a 24%(131/547) u skupinama koje su primale samo peginterferon alfa-2b i ribavirin.
In clinical trials, the proportion of subjects who received erythropoietin for the management of anaemia was 43%(667/1,548) of subjects in the Victrelis-containing arms compared to 24%(131/547) of subjects receiving peginterferon alfa-2b and ribavirin alone.